How MedSwitcher Compares GLP-1 Medications
Our goal is simple: help patients understand what changes when they switch medications. That requires more nuance than “this one is better” slapped onto mismatched trial data.
When comparing medications, we try to preserve the context of each result, including trial name, dose, duration, population, and whether the number comes from ITT, treatment-regimen, or completers analysis.
Direct cross-trial comparisons have limits. When studies use different populations or different endpoints, we say so instead of pretending the numbers line up perfectly by magic.
Switching guides are based on class effects, practical prescribing patterns, dose ladders, pharmacology, and the published information available at the time of writing. They are educational summaries, not prescriber instructions.
Whenever possible, we explain what is known, what is inferred, and where a clinician’s judgment matters most, especially during titration, maintenance, and diabetes-related use cases.
Drug pricing changes often. We separate self-pay pricing, savings card pricing, Medicare commitments, and general list price language because lumping them together creates confusion fast.
When exact current pricing is unclear, we say so and avoid pretending a promotional price applies universally across all doses and payer types.